209 related articles for article (PubMed ID: 22875636)
1. Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies.
Gröger A; Berg D
J Neural Transm (Vienna); 2012 Dec; 119(12):1523-8. PubMed ID: 22875636
[TBL] [Abstract][Full Text] [Related]
2. Analyzing the co-localization of substantia nigra hyper-echogenicities and iron accumulation in Parkinson's disease: A multi-modal atlas study with transcranial ultrasound and MRI.
Ahmadi SA; Bötzel K; Levin J; Maiostre J; Klein T; Wein W; Rozanski V; Dietrich O; Ertl-Wagner B; Navab N; Plate A
Neuroimage Clin; 2020; 26():102185. PubMed ID: 32050136
[TBL] [Abstract][Full Text] [Related]
3. In vivo detection of iron and neuromelanin by transcranial sonography--a new approach for early detection of substantia nigra damage.
Berg D
J Neural Transm (Vienna); 2006 Jun; 113(6):775-80. PubMed ID: 16755382
[TBL] [Abstract][Full Text] [Related]
4. The history of the research of iron in parkinsonian substantia nigra.
Friedman A; Galazka-Friedman J
J Neural Transm (Vienna); 2012 Dec; 119(12):1507-10. PubMed ID: 22941506
[TBL] [Abstract][Full Text] [Related]
5. Neuroimaging Correlates of Substantia Nigra Hyperechogenicity in Parkinson's Disease.
Prasuhn J; Strautz R; Lemmer F; Dreischmeier S; Kasten M; Hanssen H; Heldmann M; Brüggemann N
J Parkinsons Dis; 2022; 12(4):1191-1200. PubMed ID: 35180131
[TBL] [Abstract][Full Text] [Related]
6. Postnatal decrease in substantia nigra echogenicity. Implications for the pathogenesis of Parkinson's disease.
Iova A; Garmashov A; Androuchtchenko N; Kehrer M; Berg D; Becker G; Garmashov Y
J Neurol; 2004 Dec; 251(12):1451-4. PubMed ID: 15645343
[TBL] [Abstract][Full Text] [Related]
7. [Transcranial sonography of substantia nigra in patients with Parkinson's disease].
Miwa H
Rinsho Shinkeigaku; 2013; 53(11):981-2. PubMed ID: 24291852
[TBL] [Abstract][Full Text] [Related]
8. Iron accumulation in Parkinson's disease.
Mochizuki H; Yasuda T
J Neural Transm (Vienna); 2012 Dec; 119(12):1511-4. PubMed ID: 23070727
[TBL] [Abstract][Full Text] [Related]
9. Plasma ceruloplasmin ferroxidase activity correlates with the nigral sonographic area in Parkinson's disease patients: a pilot study.
Martínez-Hernández R; Montes S; Higuera-Calleja J; Yescas P; Boll MC; Diaz-Ruiz A; Rios C
Neurochem Res; 2011 Nov; 36(11):2111-5. PubMed ID: 21706376
[TBL] [Abstract][Full Text] [Related]
10. Disturbance of iron metabolism in Parkinson's disease -- ultrasonography as a biomarker.
Berg D; Hochstrasser H; Schweitzer KJ; Riess O
Neurotox Res; 2006 Jan; 9(1):1-13. PubMed ID: 16464747
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
[TBL] [Abstract][Full Text] [Related]
12. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease.
Hochstrasser H; Bauer P; Walter U; Behnke S; Spiegel J; Csoti I; Zeiler B; Bornemann A; Pahnke J; Becker G; Riess O; Berg D
Neurology; 2004 Nov; 63(10):1912-7. PubMed ID: 15557511
[TBL] [Abstract][Full Text] [Related]
13. Complex I, iron, and ferritin in Parkinson's disease substantia nigra.
Mann VM; Cooper JM; Daniel SE; Srai K; Jenner P; Marsden CD; Schapira AH
Ann Neurol; 1994 Dec; 36(6):876-81. PubMed ID: 7998774
[TBL] [Abstract][Full Text] [Related]
14. Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.
Guan X; Xu X; Zhang M
Neurosci Bull; 2017 Oct; 33(5):561-567. PubMed ID: 28516282
[TBL] [Abstract][Full Text] [Related]
15. Neuroimaging: current role in detecting pre-motor Parkinson's disease.
Godau J; Hussl A; Lolekha P; Stoessl AJ; Seppi K
Mov Disord; 2012 Apr; 27(5):634-43. PubMed ID: 22508281
[TBL] [Abstract][Full Text] [Related]
16. Iron histochemistry of the substantia nigra in Parkinson's disease.
Morris CM; Edwardson JA
Neurodegeneration; 1994 Dec; 3(4):277-82. PubMed ID: 7842298
[TBL] [Abstract][Full Text] [Related]
17. Iron deposition in Parkinson's disease by quantitative susceptibility mapping.
Chen Q; Chen Y; Zhang Y; Wang F; Yu H; Zhang C; Jiang Z; Luo W
BMC Neurosci; 2019 May; 20(1):23. PubMed ID: 31117957
[TBL] [Abstract][Full Text] [Related]
18. Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: implications for idiopathic and monogenetic forms.
Berg D
Neurochem Res; 2007 Oct; 32(10):1646-54. PubMed ID: 17468954
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of Parkinson's disease--transcranial sonography in relation to MRI.
Niehaus L; Boelmans K
Int Rev Neurobiol; 2010; 90():63-79. PubMed ID: 20692494
[TBL] [Abstract][Full Text] [Related]
20. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence.
Graham JM; Paley MN; Grünewald RA; Hoggard N; Griffiths PD
Brain; 2000 Dec; 123 Pt 12():2423-31. PubMed ID: 11099445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
